Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction

Vera Therapeutics, Inc.

Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.
Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.
Trial continues blinded to assess eGFR over two years, expected completion in 2027.
No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.